What is HC Wainwright’s Estimate for Altimmune Q2 Earnings?

Altimmune, Inc. (NASDAQ:ALT) – Investment analysts at HC Wainwright decreased their Q2 2025 earnings per share (EPS) estimates for shares of Altimmune in a report issued on Monday, March 3rd. HC Wainwright analyst P. Trucchio now expects that the company will earn ($0.34) per share for the quarter, down from their prior forecast of ($0.33). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Altimmune’s FY2025 earnings at ($1.34) EPS, Q1 2026 earnings at ($0.38) EPS, Q2 2026 earnings at ($0.34) EPS, Q3 2026 earnings at ($0.34) EPS, Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($1.40) EPS, FY2027 earnings at ($1.40) EPS and FY2028 earnings at ($0.14) EPS.

Altimmune (NASDAQ:ALT) last issued its earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%.

Several other brokerages have also recently commented on ALT. William Blair initiated coverage on Altimmune in a research note on Friday, February 28th. They issued a “market perform” rating for the company. Stifel Nicolaus assumed coverage on Altimmune in a research report on Wednesday, January 8th. They set a “buy” rating and a $18.00 target price for the company. Finally, UBS Group assumed coverage on Altimmune in a research report on Tuesday, November 12th. They set a “buy” rating and a $26.00 target price for the company. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $20.83.

Altimmune Stock Performance

Shares of NASDAQ ALT opened at $5.72 on Thursday. The stock has a market cap of $440.52 million, a price-to-earnings ratio of -3.69 and a beta of 0.87. The business has a 50 day simple moving average of $6.74 and a 200 day simple moving average of $7.18. Altimmune has a 52 week low of $5.28 and a 52 week high of $11.77.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ALT. Creative Planning raised its stake in shares of Altimmune by 20.5% in the third quarter. Creative Planning now owns 18,411 shares of the company’s stock valued at $113,000 after purchasing an additional 3,132 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in Altimmune by 119.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 40,705 shares of the company’s stock worth $250,000 after acquiring an additional 22,188 shares in the last quarter. Intech Investment Management LLC acquired a new position in Altimmune during the third quarter worth $207,000. Charles Schwab Investment Management Inc. raised its stake in Altimmune by 2.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock worth $1,299,000 after acquiring an additional 4,772 shares in the last quarter. Finally, Larson Financial Group LLC acquired a new position in Altimmune during the third quarter worth $31,000. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.